Suppr超能文献

肿瘤内 CD8 T 细胞凋亡是 T 细胞功能障碍的主要组成部分,并阻碍抗肿瘤免疫。

Intratumoral CD8 T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.

机构信息

Department of Pathology, University of Chicago, Chicago, Illinois.

The Committee on Immunology, University of Chicago, Chicago, Illinois.

出版信息

Cancer Immunol Res. 2018 Jan;6(1):14-24. doi: 10.1158/2326-6066.CIR-17-0249. Epub 2017 Nov 2.

Abstract

Subsets of human tumors are infiltrated with tumor antigen-specific CD8 T cells [tumor-infiltrating lymphocytes (TILs)] despite tumor progression. These TILs are thought to be inactivated by the immunosuppressive tumor microenvironment, through the engagement of inhibitory receptors such as CTLA-4 and PD-1. However, antigen-specific CD8 TILs are not functionally inert but are undergoing activation Here, we show that antigen-specific CD8 TILs are actively proliferating, yet also undergo high rates of apoptosis, leading to a vicious cycle of activation and death that limits immune efficacy. Preventing CD8 TIL apoptosis by Bcl-x overexpression enabled accumulation and improved tumor control. Effective combination immunotherapy with an agonist 4-1BB mAb plus either CTLA-4 or PD-L1 neutralization led to a marked accumulation of specific CD8 TILs through decreased apoptosis rather than increased T-cell entry or proliferation. Our data suggest that antigen-driven apoptosis of CD8 TILs is a barrier to effective spontaneous antitumor immunity and should be considered as a critical factor in the development of cancer immunotherapies. .

摘要

尽管肿瘤在不断进展,但是仍有一部分人类肿瘤被肿瘤抗原特异性 CD8 T 细胞(肿瘤浸润淋巴细胞(TILs))浸润。这些 TILs被认为被免疫抑制性肿瘤微环境通过结合抑制性受体如 CTLA-4 和 PD-1 而失活。然而,抗原特异性 CD8 TIL 并非功能上无活性,而是正在经历激活。在这里,我们发现抗原特异性 CD8 TIL 正在积极增殖,但也经历高比例的凋亡,导致激活和死亡的恶性循环,从而限制了免疫疗效。通过 Bcl-x 过表达防止 CD8 TIL 凋亡能够实现积累并改善肿瘤控制。使用激动剂 4-1BB mAb 联合 CTLA-4 或 PD-L1 中和的有效联合免疫疗法通过减少凋亡而非增加 T 细胞进入或增殖导致特定 CD8 TIL 的显著积累。我们的数据表明,抗原驱动的 CD8 TIL 凋亡是有效自发抗肿瘤免疫的障碍,应被视为癌症免疫疗法发展的关键因素。

相似文献

1
Intratumoral CD8 T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.
Cancer Immunol Res. 2018 Jan;6(1):14-24. doi: 10.1158/2326-6066.CIR-17-0249. Epub 2017 Nov 2.
3
Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
J Immunol Res. 2016;2016:8941260. doi: 10.1155/2016/8941260. Epub 2016 May 22.
4
Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
Cancer Discov. 2016 Sep;6(9):1022-35. doi: 10.1158/2159-8290.CD-15-1412. Epub 2016 Jun 13.
5
The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8 T-cell Function.
Cancer Immunol Res. 2017 Oct;5(10):920-928. doi: 10.1158/2326-6066.CIR-17-0187. Epub 2017 Sep 5.
7
Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8 T Cells is Determined by Their Differentiation Status in Glioblastoma.
Clin Cancer Res. 2019 Apr 15;25(8):2549-2559. doi: 10.1158/1078-0432.CCR-18-2564. Epub 2019 Jan 18.
9
β-Adrenergic Signaling Impairs Antitumor CD8 T-cell Responses to B-cell Lymphoma Immunotherapy.
Cancer Immunol Res. 2018 Jan;6(1):98-109. doi: 10.1158/2326-6066.CIR-17-0401. Epub 2017 Nov 16.
10
Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
Cancer Immunol Res. 2017 Dec;5(12):1109-1121. doi: 10.1158/2326-6066.CIR-17-0258. Epub 2017 Nov 2.

引用本文的文献

1
Immunogenic cell death genes in single-cell and transcriptome analyses perspectives from a prognostic model of cervical cancer.
Front Genet. 2025 Apr 7;16:1532523. doi: 10.3389/fgene.2025.1532523. eCollection 2025.
4
Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma.
JCI Insight. 2025 Mar 24;10(6):e182563. doi: 10.1172/jci.insight.182563.
5
T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 18. doi: 10.1007/s00210-025-04035-9.
10
Ferroptosis exacerbates the clonal deletion of virus-specific exhausted CD8 T cells.
Front Immunol. 2024 Nov 25;15:1490845. doi: 10.3389/fimmu.2024.1490845. eCollection 2024.

本文引用的文献

1
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.
Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9.
2
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
Science. 2017 Mar 31;355(6332):1428-1433. doi: 10.1126/science.aaf1292. Epub 2017 Mar 9.
5
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768. doi: 10.1073/pnas.1609376113. Epub 2016 Nov 11.
6
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
J Clin Invest. 2016 Sep 1;126(9):3447-52. doi: 10.1172/JCI87324. Epub 2016 Aug 15.
7
Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.
Cancer Res. 2016 Sep 15;76(18):5229-5240. doi: 10.1158/0008-5472.CAN-15-1798. Epub 2016 Jul 27.
8
Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor Rejection.
J Immunol. 2016 Apr 1;196(7):2933-8. doi: 10.4049/jimmunol.1501144. Epub 2016 Feb 22.
9
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7551-6. doi: 10.1073/pnas.1506357112. Epub 2015 Jun 1.
10
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验